2026-06-14T03:32:23Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/52272024-09-27T10:03:31Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19607

00925njm 22002777a 4500 dc Perez-Medina, Carlos author Abdel-Atti, Dalya author Tang, Jun author Zhao, Yiming author Fayad, Zahi A author Lewis, Jason S. author Mulder, Willem J M author Reiner, Thomas author 2016 The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that is predictive of therapeutic outcome in individual subjects. In a breast cancer mouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter (Zr-89-NRep) allows precise doxorubicin (DOX) quantification. Importantly, Zr-89-NRep uptake also correlates with other types of nanoparticles' tumour accumulation. Zr-89-NRep PET imaging reveals remarkable accumulation heterogeneity independent of tumour size. We subsequently demonstrate that mice with 425 mg kg(-1) DOX accumulation in tumours had significantly better growth inhibition and enhanced survival. This non-invasive imaging tool may be developed into a robust inclusion criterion for patients amenable to nanotherapy. Nat Commun. 2016; 7:11838 10.1038/ncomms11838 2041-1723 Nature Communications 27319780 http://hdl.handle.net/20.500.12105/5227 PEGYLATED LIPOSOMAL DOXORUBICIN METASTATIC BREAST-CANCER NAB-PACLITAXEL OVARIAN-CANCER DRUG-DELIVERY TUMOR NANOMEDICINES MANAGEMENT ONCOLOGY IMPACT Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy